Infectious Diseases News and Research

RSS

Blood research could improve treatment for injured soldiers on the battlefield

Blood research conducted by biomedical engineers from The University of Texas at San Antonio College of Engineering, in collaboration with the Blood Research Program of the U.S. Army Institute of Surgical Research, could change the way injured soldiers are treated on the battlefield.

4 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.

4 Jun 2015

New mobile app may help adolescents make more informed decisions about sexual behavior

Teenagers, parents, educators and clinicians will have a new tool to help adolescents make more informed decisions about their sexual behavior. "Seventeen Days," a mobile app based on the interactive movie of the same name, will be available at no cost on iPhone, iPad and Android devices beginning June 4.

3 Jun 2015

Intermountain Healthcare participates in antibiotic stewardship forum at the White House

Intermountain Healthcare is one of 150 organizations in the nation that was invited to the White House to help develop national policy to address the growing problem of the overuse of antibiotics.

3 Jun 2015

Portable microendoscope could eliminate need for costly biopsies for esophageal cancer patients

In a clinical study of patients in the United States and China, researchers found that a low-cost, portable, battery-powered microendoscope developed by Rice University bioengineers could eventually eliminate the need for costly biopsies for many patients undergoing standard endoscopic screening for esophageal cancer.

3 Jun 2015

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.

2 Jun 2015

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.

2 Jun 2015

Telbivudine drug prevents perinatal transmission of HBV

The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

2 Jun 2015

Consultation process launched to support development of Federal Framework on Lyme Disease

Today, the Chief Public Health Officer of Canada Dr. Gregory Taylor launched a consultation process to support the development of a Federal Framework on Lyme Disease.

2 Jun 2015

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, today announced a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress.

2 Jun 2015

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria).

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

Group Health Research Institute conducted the first randomized trial to test an intervention aimed at improving hesitancy about early childhood vaccines by working directly with doctors. Vax Northwest, a Washington state public-private partnership, developed the intervention.

2 Jun 2015

BiondVax provides update on financial results for first quarter 2015

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the first quarter of 2015 and provided a business update.

1 Jun 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Duke researchers reveal how bladder cells can eject UTI-causing bacteria

Duke Medicine researchers have found that bladder cells have a highly effective way to combat E. coli bacteria that cause urinary tract infections (UTIs).

29 May 2015

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Clinical trial suggests HIV patients should start therapy sooner rather than later

Findings from a large-scale clinical trial have shown that people with HIV should start antiretroviral therapy as soon as they have been diagnosed, irrespective of what their CD4+ count is...

28 May 2015

Infectious Diseases News and Research

Blood research could improve treatment for injured soldiers on the battlefield

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

New mobile app may help adolescents make more informed decisions about sexual behavior

Intermountain Healthcare participates in antibiotic stewardship forum at the White House

Portable microendoscope could eliminate need for costly biopsies for esophageal cancer patients

New finding may lead to development of immunity-based therapies for tuberculosis

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Telbivudine drug prevents perinatal transmission of HBV

Consultation process launched to support development of Federal Framework on Lyme Disease

Neutrolin post marketing surveillance data presented at 52nd ERA-EDTA Congress

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Group Health Research Institute conducts first randomized trial to tackle vaccine hesitancy

BiondVax provides update on financial results for first quarter 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Duke researchers reveal how bladder cells can eject UTI-causing bacteria

iCo Therapeutics reports financial results for first quarter 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Clinical trial suggests HIV patients should start therapy sooner rather than later

Industry Focus: Infectious Diseases eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News